预约演示

更新于：2025-01-23

NRP-1

更新于：2025-01-23

基本信息

别名

CD304、neuropilin 1、Neuropilin-1

+ [5]

简介

Cell-surface receptor involved in the development of the cardiovascular system, in angiogenesis, in the formation of certain neuronal circuits and in organogenesis outside the nervous system. Mediates the chemorepulsant activity of semaphorins (PubMed:9288753, PubMed:9529250, PubMed:10688880). Recognizes a C-end rule (CendR) motif R/KXXR/K on its ligands which causes cellular internalization and vascular leakage (PubMed:19805273). It binds to semaphorin 3A, the PLGF-2 isoform of PGF, the VEGF165 isoform of VEGFA and VEGFB (PubMed:9288753, PubMed:9529250, PubMed:10688880, PubMed:19805273). Coexpression with KDR results in increased VEGF165 binding to KDR as well as increased chemotaxis. Regulates VEGF-induced angiogenesis. Binding to VEGFA initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development (By similarity). Regulates mitochondrial iron transport via interaction with ABCB8/MITOSUR (PubMed:30623799). Binds VEGF-165 and may inhibit its binding to cells (PubMed:10748121, PubMed:26503042). May induce apoptosis by sequestering VEGF-165 (PubMed:10748121). May bind as well various members of the semaphorin family. Its expression has an averse effect on blood vessel number and integrity. (Microbial infection) Acts as a host factor for human coronavirus SARS-CoV-2 infection. Recognizes and binds to CendR motif RRAR on SARS-CoV-2 spike protein S1 which enhances SARS-CoV-2 infection.

关联

项与 NRP-1 相关的药物

Certepetide

靶点

CD51 x NRP-1

作用机制

CD51拮抗剂 [+1]

在研机构

Lisata Therapeutics, Inc. [+3]

原研机构

Cend Therapeutics, Inc.初创企业

在研适应症

胰腺导管腺癌 [+16]

非在研适应症

转移性胰腺癌

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

ASP-1948

靶点

NRP-1

作用机制

NRP-1抑制剂

在研机构

Astellas Pharma Global Development, Inc.

原研机构

Astellas Pharma, Inc.

在研适应症

局部晚期恶性实体瘤

非在研适应症-

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期1800-01-20

FOL-005

靶点

NRP-1

作用机制

NRP-1 激动剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期1800-01-20

项与 NRP-1 相关的临床试验

NCT06592664

/ Not yet recruiting临床1/2期

A Phase 1b/2a, Double-blind, Placebo-controlled, Three Arm, Randomized Study Evaluating Continuous Infusion of LSTA1 Over 4 Hours When Added to Standard of Care (SoC) Versus a Single Intravenous (IV) Push of LSTA1 When Added to SoC, Versus SoC Alone in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Who Have Progressed on FOLFIRINOX (FORTIFIDE)

The goal of this clinical trial is to test a new drug plus standard treatment compared with standard treatment alone in people with metastatic pancreatic ductal adenocarcinoma.
The main questions it aims to answer are:
* is the new drug plus standard treatment safe and tolerable
* is the new drug plus standard treatment more effective than standard treatment
Participants will:
* Visit the clinic three times every 28 days for treatment and tests
* Have CT or MRI scans every 8 weeks while on treatment

开始日期2025-03-01

申办/合作机构

Lisata Therapeutics, Inc.

NCT06592664

/ Not yet recruiting临床1/2期

开始日期2024-12-01

申办/合作机构

Lisata Therapeutics, Inc.

NCT06261359

/ Recruiting临床2期

A Phase II, Randomized, Double-blind, Multi-center, Placebo-Controlled Study of the Efficacy and Safety of CEND-1 in Combination With Chemotherapy as First-Line Therapy in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma

The purpose of this study is to evaluate the efficacy and safety of CEND-1 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo as first-line treatment in patients with Locally Advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma.

开始日期2024-03-19

申办/合作机构

齐鲁制药有限公司

100 项与 NRP-1 相关的临床结果

登录后查看更多信息

100 项与 NRP-1 相关的转化医学

登录后查看更多信息

0 项与 NRP-1 相关的专利（医药）

登录后查看更多信息

2,686

项与 NRP-1 相关的文献（医药）

2025-03-01·Angiogenesis

Neuropilin-1 controls vascular permeability through juxtacrine regulation of endothelial adherens junctions

Article

作者: Pal, Sagnik ; Claesson-Welsh, Lena ; Su, Yangyang ; Nwadozi, Emmanuel ; Richards, Mark

AbstractNeuropilin-1 (NRP1) regulates endothelial cell (EC) biology through modulation of vascular endothelial growth factor receptor 2 (VEGFR2) signalling by presenting VEGFA to VEGFR2. How NRP1 impacts VEGFA-mediated vascular hyperpermeability has however remained unresolved, described as exerting either a positive or a passive function. Using EC-specific Nrp1 knock-out mice, we discover that EC-expressed NRP1 exerts an organotypic role. In the ear skin, VEGFA/VEGFR2-mediated vascular leakage was increased following loss of EC NRP1, implicating NRP1 in negative regulation of VEGFR2 signalling. In contrast, in the back skin and trachea, loss of EC NRP1 decreased vascular leakage. In accordance, phosphorylation of vascular endothelial (VE)-cadherin was increased in the ear skin but suppressed in the back skin of Nrp1 iECKO mice. NRP1 expressed on perivascular cells has been shown to impact VEGF-mediated VEGFR2 signalling. Importantly, expression of NRP1 on perivascular cells was more abundant in the ear skin than in the back skin. Global loss of NRP1 resulted in suppressed VEGFA-induced vascular leakage in the ear skin, implicating perivascular NRP1 as a juxtacrine co-receptor of VEGFA in this compartment. Altogether, we demonstrate that perivascular NRP1 is an active participant in EC VEGFA/VEGFR2 signalling and acts as an organotypic modifier of EC biology.

2025-02-01·Developmental Biology

Semaphorin 3A repulsion directs the caudal projection of pioneer longitudinal axons in the developing chicken brain

Article

作者: Schubert, Frank R ; Dietrich, Susanne ; Riley, Kerry-Lyn

The medial longitudinal fasciculus (MLF) is the first axon tract to develop in the ventral vertebrate brain. It originates in the diencephalon and projects caudally into the spinal cord, pioneering the path for later developing axons. Previous anatomical and expression analyses in the chicken suggested Semaphorin 3 A (Sema3A) as the candidate to repel the amniote MLF from the forebrain. However, studies in the zebrafish implicated a distantly related semaphorin with a role in axon fasciculation, not guidance. Thus, the mechanism accounting for the caudal projection of the MLF remains unclear. Here we show that misexpression of Sema3A or grafting of Sema3A-expressing cells into the path of the MLF diverts the axons or blocks their outgrowth in chicken embryos. In vitro, Sema3A exposure resulted in the collapse of MLF growth cones. A dominant-negative approach or siRNA to interfere with the function of the Sema3A receptor Neuropilin1 allowed MLF axons to project rostrally. Together, this suggests that Sema3a repulsion directs the caudal extension of the MLF to pioneer the ventral longitudinal tract.

2025-02-01·Neurochemical Research

TAG-1 Regulates NRP1 in Schwann Cells and Participates in Regulating Nerve Regeneration in Rats with Sciatic Nerve Crush Injury

Article

作者: Sun, Xu-Ri ; Zhou, Qing-Sheng ; Wang, Hui-Min ; An, Xue ; Li, Min ; Xu, Xiao-Dan ; Liu, Pei-Sheng

Schwann cells (SCs) are necessary for peripheral nerve regeneration due to their plasticity and trophic supply after sciatic nerve injury (SNI). However, the multiple adaptations of SCs are still poorly understood. This study explored the effects of transient axonal glycoprotein type-1 (TAG-1) on cell migration and neuropilin1 (NRP1) expression in SCs and examined the impact of TAG-1 on nerve regeneration in rats with SNI. The expression of TAG-1 and NRP1 in SCs, RSC96 cells, was measured using co-immunoprecipitation and immunofluorescence. TAG-1 silence in RSC96 cells was established by TAG-1 siRNA transfection. The effects of TAG-1 silence on cell migration and NRP1 expression were measured in cells. Male adult Wistar rats suffered sciatic nerve crush injury and were treated with exogenous TAG-1 protein. The sciatic function was observed every week. The histological changes of sciatic nerves and expressions of S100β, NRP1, GAP43, and NCAM in the nerves were observed after injury 28 days. The TAG-1 and NRP1 were expressed in the RSC96 cells, and there was an interaction between TAG-1 and NRP1. TAG-1 silence suppressed the cell migration and NRP1 expression in cells. In rats with SNI, the TAG-1 treatment improved the sciatic function and promoted nerve regeneration by increasing the expressions of S100β, NRP1, GAP-43, and NCAM in the nerves. This study showed that TAG-1 regulated cell migration and NRP1 expression in SCs, and TAG-1 treatment might be a strategy for nerve regeneration after the SNI.

项与 NRP-1 相关的新闻（医药）

2024-12-02

·ioncology

SABCS 2024丨盛幕将启，中国专家入选壁报展示（Poster Session 1）

点击蓝字，关注我们编者按：第47届圣安东尼奥乳腺癌研讨会（SABCS）将于当地时间2024年12月10日至13日在美国得克萨斯州圣安东尼奥举行。SABCS是全球最大的乳腺癌领域盛会，来自102个国家的超过1万名注册参会者将在为期四天的会议中展示1886篇被接受的论文摘要。肿瘤瞭望特别整理中国专家被收录的壁报内容，以飨读者。（注：因官网未公布详细作者单位，如有遗漏或错误，欢迎留言指正。） Poster Session 1 日期：12月11日时间：12:30～2:00 p.m 地点：Halls 2-3 P1-01-04：EPLIN and EPLIN responsive protein APOC3 in breast cancer EPLIN及其应答蛋白APOC3在乳腺癌中的作用报告作者：Cai Wang P1-02-12: Prospective phase II study on the efficacy and safety of hetrombopag for the treatment of cancer therapy-induced thrombocytopenia in patients with breast cancer 在乳腺癌患者中应用海曲泊帕治疗癌症治疗诱导的血小板减少症的有效性和安全性的前瞻性II期研究报告作者：Hanfang Jiang P1-02-18: Cancer-Associated Fibroblast-Mediated Suppression of T Cell Activity as a mechanism of Resistance to Immunoradiotherapy in Breast Cancer 癌症相关成纤维细胞介导的T细胞活性抑制作为乳腺癌免疫放疗抵抗的机制报告作者：Rongrong Wu P1-04-04: evelopment and validation of a nomogram for axillary lymph node metastasis risk in breast cancer 乳腺癌腋窝淋巴结转移风险列线图的建立和验证报告作者：Xiaoyun Mao P1-04-12: Optimizing Tolerability of Pyrotinib in HER2-Positive EarlyStage High-Risk Breast Cancer: A Multicenter, Randomized, ThreeCohort Study 优化吡咯替尼治疗HER2阳性早期高危乳腺癌的耐受性：一项多中心、随机、三队列研究报告作者：Qiao Cheng P1-04-22: Loss of SMAD4 Drives Breast Cancer Invasion and Metastasis through E2F1-Mediated Activation of the PEG10-ERK Axis SMAD4缺失通过E2F1介导的PEG10-ERK轴激活驱动乳腺癌的侵袭和转移报告作者：Dan Shu P1-04-25: Fast and accurate detection of tumor-immune cell interactions with deep learning 利用深度学习快速准确地检测肿瘤-免疫细胞相互作用报告作者：Huiping Liu P1-05-07: Expression of ATP6AP2 in clinical breast cancer and the prognostic and therapeutic value in ERBB2 subtype of breast cancer ATP6AP2在临床乳腺癌中的表达及其在ERBB2亚型乳腺癌中的预后和治疗价值报告作者：Jia Tong P1-05-24: Biomarkers and Spatial Determinants of SHR-A1811 Efficacy in Neoadjuvant Treatment for HER2-Positive Breast Cancer SHR-A1811在HER2阳性乳腺癌新辅助治疗中疗效的生物标志物和空间决定因素报告作者：Zhi-Ming Shao P1-05-27: Analytical comparison of tissue-based next-generation sequencing assays for the detection of PIK3CA, AKT1, and PTEN tumor alterations in breast cancer 基于组织的二代测序检测乳腺癌中PIK3CA、AKT1和PTEN肿瘤改变的分析比较报告作者：Xiaodun Li P1-06-04: Psychological stress and its correlations to patients with acute lymphedema after breast cancer surgery 心理应激与乳腺癌术后急性淋巴水肿的相关性研究报告作者：Li-Chen Tang P1-06-06: Oral cyclophosphamide-induced hemorrhagic cystitis from metronomic Cyclophosphamide/Methotrexate/5-Fluorouracil for treatment of synchronous bilateral breast cancer – A case report 口服环磷酰胺导致出血性膀胱炎：一例应用节拍化疗方案环磷酰胺/甲氨蝶呤/5-氟尿嘧啶治疗同期双侧乳腺癌的病例报告报告作者：Jina Yun P1-06-24: Single-cell RNA sequencing reveals the role of HSPA1B+ immune cells in breast cancer microenvironment remodeling during neoadjuvant chemotherapy 单细胞RNA测序揭示HSPA1B+免疫细胞在乳腺癌新辅助化疗微环境重塑中的作用报告作者：Zihan Zhai P1-06-29: Targeting NRP1 reduces triple-negative breast cancer lung metastasis and improves immunotherapy efficacy 靶向NRP1可降低三阴性乳腺癌肺转移，并提高免疫治疗疗效报告作者：Zhuxi Duan P1-07-20: Mechanism of miR-221-3p/PARP1 regulating the progression of triple-negative breast cancer through the NF-κB pathway miR-221-3p/PARP1通过NF-κB通路调控三阴性乳腺癌进展的机制报告作者：Qianqian Lei P1-07-21: Efficacy of CDK4/6 Inhibitor Abemaciclib in Metastatic Triple-Negative Breast Cancer CDK4/6抑制剂阿贝西利治疗转移性三阴性乳腺癌的疗效报告作者：Chuling Zhuang P1-07-25: E3 ubiquitin-protein ligase RNF40 promotes triplenegative breast cancer progression and metastasis by promoting TRIM28 expression and stabilizing TWIST1 protein E3泛素蛋白连接酶RNF40通过促进TRIM28表达和稳定TWIST1蛋白促进三阴性乳腺癌的进展和转移报告作者：Junjiang Fu P1-07-28: Real-World Study on Efficacy and Safety of SG Alone and Combined with Immunotherapy in Metastatic Triple Negative Breast Cancer Patients SG单药及联合免疫治疗转移性三阴性乳腺癌患者的疗效和安全性的真实世界研究报告作者：Jianli Zhao P1-08-02: HIF-1-dependent expression of integrin β3 incorporated into extracellular vesicles promotes metastasis of breast cancer cells to the brain HIF-1依赖的整合素β3表达整合入细胞外囊泡中，促进乳腺癌细胞向脑的转移报告作者：Yongkang Yang P1-08-05: The mechanism of FOXO3a in coping with oxidative stress to promote TNBC progression FOXO3a应对氧化应激促进TNBC进展的机制报告作者：Manqing Cao P1-08-21: Synchronous female breast cancer and follicular lymphoma in a single patient: A case report 女性乳腺癌同时合并滤泡性淋巴瘤一例报告报告作者：Zijun Zhao P1-09-05: Simultaneous 3D Mapping of RNA and Protein to Advance Personalized Medicine in Breast Cancer 同时进行RNA和蛋白质的3D绘图以推进乳腺癌的个体化治疗报告作者：Yue Li P1-09-11: Machine Learning based analysis in chemotherapy resistant triple negative breast cancer 基于机器学习的化疗耐药三阴性乳腺癌分析报告作者：Dongling Wu P1-09-24: Cancer cell-derived exosomal miR-20a-5p inhibits CD8+ T-cell function and confers anti-programmed cell death 1 therapy resistance in triple-negative breast cancer 三阴性乳腺癌细胞衍生的外泌体miR-20a-5p抑制CD8+ T细胞功能并导致抗程序性细胞死亡1治疗耐药报告作者：XIANGDONG BAI P1-10-17: HER2+ breast cancer diagnosed in the 2nd trimester of pregnancy 妊娠中期诊断的HER2+乳腺癌报告作者：Shiliang Zhang P1-11-01: Immune Infiltration Correlates with Transcriptomic Subtypes in Primary ER+ Invasive Lobular Breast Cancer 原发性ER+浸润性小叶乳腺癌的免疫浸润与转录组亚型相关报告作者：Fangyuan Chen P1-11-07: Associations between Breast Cancer Index Classifications and MSK-IMPACT Genomic Profiles in HR+/HER2- Breast Cancer HR+/HER2-乳腺癌中乳腺癌指数分类与MSK-IMPACT基因组谱的相关性报告作者：Hong Zhang P1-11-11: Pathological Complete Response and Survival Outcomes ofSingle Hormone Receptor-Positive/HER2-Negative Breast Cancer after Neoadjuvant Treatment and Further analysis of its Intrinsic Biological Features and Immune Landscape. 新辅助治疗后单激素受体阳性/HER2阴性乳腺癌的病理完全缓解及生存结局，以及对其内在生物学特征和免疫图谱的进一步分析报告作者：Lei Ji P1-11-12: Early-stage HR+/HER2- breast cancer patients under 50 years old with a low-risk identified by the 70-gene signature (MammaPrintTM) could benefit from ovarian function suppression: A real-world study in China. 基于70基因特征（MammaPrintTM）鉴定为低风险的50岁以下早期HR+/HER2-乳腺癌患者可从卵巢功能抑制中获益：一项中国真实世界研究报告作者：Weijuan Jia P1-11-13: Development and Validation of a Deep Learning Model for HR+/HER2- Early-stage Breast Cancer Recurrence Prediction (HERPAI) using Conventional Clinical and Pathological Data: A Realworld Study in Chinese Population 基于常规临床和病理数据构建并验证用于HR+/HER2-早期乳腺癌复发预测的深度学习模型（HERPAI）：一项针对中国人群的真实世界研究报告作者：Ruixin Pan P1-12-09: Real-world prescribing patterns and outcomes of CDK4/6 inhibitors in elderly patients with metastatic HR+/HER2- breast cancer CDK4/6抑制剂在老年转移性HR+/HER2-乳腺癌患者中的真实世界处方模式和结局报告作者：Xiao-Wei Tan P1-12-26: Clinical Case Vignette - Molecular PET Imaging to Guide Selection for Endocrine Therapy in Estrogen-Receptor Positive Metastatic Breast Cancer 临床病例简述——分子PET成像指导雌激素受体阳性转移性乳腺癌内分泌治疗的选择报告作者：Wenhui Zhou P1-12-27: Clinical Case Vignette: Estrogen Receptor Targeting PET Imaging to Monitor Treatment Response to Endocrine Therapy in Lobular Breast Cancer 临床病例简述：雌激素受体靶向PET显像监测乳腺小叶癌内分泌治疗的疗效报告作者：Wenhui Zhou （来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床结果

2024-10-21

·PipelineReview

Find Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of FTX-101

MONTREAL, Canada I October 21, 2024 I Find Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, today announced initiation of dosing in its Phase 1 clinical study of FTX-101 in healthy volunteers. FTX-101 is a first-in-class therapeutic peptide that modulates the Plexin A1 / Neuropilin 1 transmembrane receptor complex in the brain to promote remyelination. Following completion of the Phase 1 clincal study, Find plans to investigate the use of FTX-101 in individuals with Chronic Optic Neuropathy – a long-term condition due to demyelination in the visual tracts of the brain and optic nerve, with serious effects on visual acuity and perception. The Phase 1 first-in-human study will assess the safety, tolerability, and pharmacokinetics of FTX-101 when administered in healthy volunteers. The study is being initiated after the US Food and Drug Administration authorized initiation of the study earlier this year. The clinical study consists of two parts. Part 1 is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study comprised of 40 subjects receiving FTX-101 or placebo while Part 2 is a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study that will enroll 24 subjects receiving FTX-101 or placebo. “The initiation of this study is a significant milestone for both our company and individuals who suffer with Chronic Optic Neuropathy,” said Philippe Douville, CEO of Find. “In this study, we will build on the large body of preclinical evidence demonstrating FTX-101’s effects in models of autoimmune disease. A therapy of this type would represent a major step forward in finding the first treatment to improve the lives of people afflicted with Chronic Optic Neuropathy. We look forward to sharing data from this study in the first half of 2025.” About FTX-101 Find’s lead compound, FTX-101, is a first-in-class remyelinating agent that aims to restore vision to people suffering from Chronic Optic Neuropathy. FTX-101 is a rationally designed therapeutic peptide that targets Plexin A1 and Neuropilin 1, a receptor complex present in the brain that has been shown to be involved in the migration and differentiation of oligodendrocyte precursor cells into myelinating oligodendrocytes. Compelling preclinical data for FTX-101 in demyelinating models show strong myelin repair activity. About Find Find Therapeutics is clinical-stage biopharmaceutical company dedicated to the development of next generation therapies to treat inflammatory autoimmune diseases. The company was launched in 2020 and is supported with investments from CTI Life Sciences, adMare BioInnovations, Domain Therapeutics and Investissment Québec and an exclusive license from SATT-Conectus and the University of Strasbourg on a technology and related know-how. Visit www.findtherapeutics.com for more details about Find Therapeutics. SOURCE: Find Therapeutics

临床1期引进/卖出

2024-10-21

·PRNewswire

Find Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of FTX-101

MONTREAL, Oct. 21, 2024 /PRNewswire/ - Find Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, today announced initiation of dosing in its Phase 1 clinical study of FTX-101 in healthy volunteers. FTX-101 is a first-in-class therapeutic peptide that modulates the Plexin A1 / Neuropilin 1 transmembrane receptor complex in the brain to promote remyelination. Following completion of the Phase 1 clincal study, Find plans to investigate the use of FTX-101 in individuals with Chronic Optic Neuropathy – a long-term condition due to demyelination in the visual tracts of the brain and optic nerve, with serious effects on visual acuity and perception. The Phase 1 first-in-human study will assess the safety, tolerability, and pharmacokinetics of FTX-101 when administered in healthy volunteers. The study is being initiated after the US Food and Drug Administration authorized initiation of the study earlier this year. The clinical study consists of two parts. Part 1 is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study comprised of 40 subjects receiving FTX-101 or placebo while Part 2 is a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study that will enroll 24 subjects receiving FTX-101 or placebo. "The initiation of this study is a significant milestone for both our company and individuals who suffer with Chronic Optic Neuropathy," said Philippe Douville, CEO of Find. "In this study, we will build on the large body of preclinical evidence demonstrating FTX-101's effects in models of autoimmune disease. A therapy of this type would represent a major step forward in finding the first treatment to improve the lives of people afflicted with Chronic Optic Neuropathy. We look forward to sharing data from this study in the first half of 2025." About FTX-101 Find's lead compound, FTX-101, is a first-in-class remyelinating agent that aims to restore vision to people suffering from Chronic Optic Neuropathy. FTX-101 is a rationally designed therapeutic peptide that targets Plexin A1 and Neuropilin 1, a receptor complex present in the brain that has been shown to be involved in the migration and differentiation of oligodendrocyte precursor cells into myelinating oligodendrocytes. Compelling preclinical data for FTX-101 in demyelinating models show strong myelin repair activity. About Find Find Therapeutics is clinical-stage biopharmaceutical company dedicated to the development of next generation therapies to treat inflammatory autoimmune diseases. The company was launched in 2020 and is supported with investments from CTI Life Sciences, adMare BioInnovations, Domain Therapeutics and Investissment Québec and an exclusive license from SATT-Conectus and the University of Strasbourg on a technology and related know-how. Visit for more details about Find Therapeutics. SOURCE Find Therapeutics Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床1期引进/卖出

分析

对领域进行一次全面的分析。

或

查看完整样例数据

来和芽仔聊天吧

立即开始免费试用!

智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。

立即开始数据试用!

智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。